Please login to the form below
1
Revenue 2017Pfizer
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Pfizer's sales performance.
J&J’s Erleada cleared for early prostate cancer in Europe
Signals competiton for Xtandi. Johnson &Johnson has bagged EU approval for Erleada for non-metastatic, castration-resistant prostate cancer (nmCRPC), setting up a market challenge with Astellas and Pfizer’s Xtandi. ... Pfizer said the split of revenues
NICE gives Lilly’s Verzenios chance to compete with rivals
Novartis’ Kisqali (ribociclib) is far behind Pfizer’s drug (but expected to hit $1.6bn in 2022 according to EvaluatePharma), with Verzenios expected to give Kisquali competition for second place in
EU approval for Opdivo combo in renal cell cancer
The CheckMate -214 trial showed the combination was superior to current standard, Pfizer’s Sutent (sunitinib), in extending overall survival, though data was limited to a subset of patients with intermediate ... However, the company has its IO rivals
Global ban on pharma freebies, including cultural gifts
Many multinational pharmaceutical companies such as Pfizer, AstraZeneca and Novartis have already instituted global bans on gifts in recent years.
Pfizer takeover rumour ignites Amarin shares
Smaller acquisitions could well be on the cards however, with Bourla suggesting that Pfizer will be “aggressive” in business development. ... Analysts at Jefferies think the product could bring in $2bn at peak, so it will be interesting to see how
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Director
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Medical Writer
-
Salary TBC
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Associate Director
-
£75, 000-90, 000
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
- NHS regional footprints
- Not another weight-loss ad
- GENERATION Z IS FEARFUL FOR THE FUTURE OF UK HEALTH SERVICES, SAYS NEW REPORT
- UK businesses leaning towards second Brexit vote
- Meet Porterhouse Medical at the ISMPP EU meeting 2019 in London 22 - 23 January
- Immunomedics craters after FDA rejects breast cancer ADC
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
